Skip to main content
SpringerLink
Log in
Book cover

Drug Interactions in Infectious Diseases pp 215–254Cite as

Quinolones

  • Chapter

Part of the book series: Infectious Disease ((ID))

Abstract

Drug-drug interactions can be categorized into those originating from pharmacokinetic mechanisms and those originating from pharmacodynamic mechanisms. Pharmacokinetic interactions are those that result in alterations of drug absorption, distribution, metabolism, and elimination; pharmacodynamic interactions occur when one drug affects the actions of another drug. This chapter deals only with the pharmacokinetic and pharmacodynamic interactions of fluoroquinolone (hereafter referred to as quinolone) with non-antimicrobial agents. Additive, synergistic, or antagonistic antimicrobial activity interactions between quinolones and other antimicrobials are not discussed.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yuk JH, Williams TW Jr. Drug interaction with quinolone antibiotics in intensive care unit patients [letter]. Arch Intern Med 1991;151:619.

    Article  PubMed  CAS  Google Scholar 

  2. Lomaestro BM, Lesar TS. Concurrent administration of ciprofloxacin and potentially interacting drugs [letter]. Am J Hosp Pharm 1989;46:1770.

    PubMed  CAS  Google Scholar 

  3. Bowes J, Graffunder EM, Lomaestro B, Venezia RA. Concomitant administration of drugs known to decrease the systemic availability of gatifloxacin. Pharmacotherapy 2002;22:800–801.

    Article  PubMed  Google Scholar 

  4. Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids [letter]. Eur J Clin Microbiol 1985;4:345.

    Article  PubMed  CAS  Google Scholar 

  5. Shiba K, Saito A, Shimada J, et al. Interactions of fleroxacin with dried aluminum hydroxide gel and probenecid. Rev Infect Dis 1989;11(suppl 5):S1097–S1098.

    Google Scholar 

  6. Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother 1992;36:2270–2274.

    PubMed  CAS  Google Scholar 

  7. Campbell NRC, Kara M, Hasinoff B, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol 1992;33:115–116.

    PubMed  CAS  Google Scholar 

  8. Okhamafe AO, Akerele JO, Chukuka CS. Pharmacokinetic interactions of norfloxacin with some metallic medicinal agents. Int J Pharm 1991;68:11–18.

    Article  CAS  Google Scholar 

  9. Akerele JO, Akhamafe AO. Influence of co-administered metallic drugs on ofloxacin pharmacokinetics. J Antimicrob Chemother 1991;28:87–94.

    Article  PubMed  CAS  Google Scholar 

  10. Sanchez Navarro A, Martinez Cabarga M, Dominguez-Gil Hurle A. Oral absorption of ofloxacin administered together with aluminum. Antimicrob Agents Chemother 1994;38:2510–2512.

    Google Scholar 

  11. Martinez Cabarga M, Sanchez Navarro A, Colino Gandarillas CI, Dominguez-Gil A. Effects of two cations on gastrointestinal absorption of ofloxacin. Antimicrob Agents Chemother 1991;35:2102–2105.

    Google Scholar 

  12. Rambout L, Sahai J, Gallicano K, Oliveras L, Garber G. Effect of bismuth subsalicylate on ciprofloxacin bioavailability. Antimicrob Agents Chemother 1994;38:2187–2190.

    PubMed  CAS  Google Scholar 

  13. Sahai J, Healy D, Stotka J, Polk R. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol 1993;35:302–304.

    PubMed  CAS  Google Scholar 

  14. Frost DW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri J. Effect of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1992;36:830–832.

    PubMed  CAS  Google Scholar 

  15. Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids [letter]. Lancet 1986;2:294.

    Article  PubMed  CAS  Google Scholar 

  16. Lomaestro BM, Baillie GR. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1991;35:1004–1007.

    PubMed  CAS  Google Scholar 

  17. Sanchez Navarro A, Martinez Cabarga M, Dominguez-Gil Hurle A. Comparative study of the influence of Ca2+ on absorption parameters of ciprofloxacin and ofloxacin. J Antimicrob Chemother 1994;34:119–125.

    Article  Google Scholar 

  18. Lomaestro BM, Baillie GR. Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. Ann Pharmacother 1993;27:1325–1328.

    PubMed  CAS  Google Scholar 

  19. Lacreta FP, Kaul S, Kollia GD, Duncan G, Randall DM, Grasela DM. Pharmacokinetics (PK) and safety of gatifloxacin in combination with ferrous sulfate or calcium carbonate in healthy volunteers. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1999. Abstract 198.

    Google Scholar 

  20. Lehto P, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther 1994;56:477–482.

    Article  PubMed  CAS  Google Scholar 

  21. Stass H, Wandel C, Delesen H, Moller JG. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet 2001;40(suppl 1):27–32.

    Article  PubMed  CAS  Google Scholar 

  22. Pletz MW, Petzold P, Allen A, Burkhardt O, Lode H. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Antimicrob Agents Chemother 2003;47:2158–2160.

    Article  PubMed  CAS  Google Scholar 

  23. Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother 1990;34:432–435.

    PubMed  CAS  Google Scholar 

  24. Flor S, Guay DRP, Opsahl JA, et al. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother 1990;34:2436–2438.

    PubMed  CAS  Google Scholar 

  25. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kid Dis 2003;42:1253–1259.

    Article  PubMed  CAS  Google Scholar 

  26. Kato R, Ueno K, Imano H, et al. Impairment of ciprofloxacin absorption by calcium polycarbophil. J Clin Pharmacol 2002;42:806–811.

    Article  PubMed  CAS  Google Scholar 

  27. Neuhofel AL, Wilton JH, Victory JM, Hejmanowsky LG, Amsden GW. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol 2002;42:461–466.

    Article  PubMed  CAS  Google Scholar 

  28. Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers. J Clin Pharmacol 2003;43:92–96.

    Article  PubMed  CAS  Google Scholar 

  29. Amsden GW, Whitaker A-M, Johnson PW. Lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal. J Clin Pharmacol 2003;43:990–995.

    Article  PubMed  CAS  Google Scholar 

  30. Sahai J, Gallicano K, Oliveros L, Khaliq S, Hawley-Foss N, Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;53:292–297.

    Article  PubMed  CAS  Google Scholar 

  31. Knupp CA, Barbhaiya RH. A multiple-dose pharmacokinetic interaction study between didanosine (Videx®) and ciprofloxacin (Cipro®) in male subjects seropositive for HIV but asymptomatic. Biopharm Drug Dispos 1997;18:65–77.

    Article  PubMed  CAS  Google Scholar 

  32. Damle BD, Mummaneni V, Kaul S, Knupp C. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother 2002;46:385–391.

    Article  PubMed  CAS  Google Scholar 

  33. Kara M, Hasinoff BB, McKay D, Campbell NRC. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 1991;31:257–261.

    PubMed  CAS  Google Scholar 

  34. Polk RE, Healy DP, Sahai J, et al. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841–1844.

    PubMed  CAS  Google Scholar 

  35. Lehto P, Kivisto KT, Neuvonen PJ. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 1994;37:82–85.

    PubMed  CAS  Google Scholar 

  36. Shiba K, Sakamoto M, Saito A, et al. Effect of ferrous sulfate, tea, and milk on absorption of AM-1155, a 6-fluoro-8-methyoxy quinolone, in humans. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1995. Abstract A43.

    Google Scholar 

  37. Stass H, Kubitza D. Effect of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Clin Pharmacokinet 2001;40(suppl 1):57–62.

    Article  PubMed  CAS  Google Scholar 

  38. Allen A, Bygate E, Faessel H, Isaac L, Lewis A. The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents 2000;15:283–289.

    Article  PubMed  CAS  Google Scholar 

  39. Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700–705.

    Article  PubMed  CAS  Google Scholar 

  40. Hoffken G, Lode H, Wiley R, et al. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis 1988;10(suppl 1):S138–S139.

    Google Scholar 

  41. Grasela TH Jr, Schentag JJ, Sedman AT, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother 1989;33:615–617.

    PubMed  CAS  Google Scholar 

  42. Lober S, Ziege S, Rau M, et al. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother 1999;43:1067–1071.

    PubMed  CAS  Google Scholar 

  43. Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother 1992;36:1219–1224.

    PubMed  CAS  Google Scholar 

  44. Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinet 2001;40(suppl 1):39–48.

    Article  PubMed  CAS  Google Scholar 

  45. Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids and sucralfate. Rev Infect Dis 1989;11(supp 5):S1096.

    Google Scholar 

  46. Maesen FPV, Davies BI, Geraedts WH, Sumajow CA. Ofloxacin and antacids [letter]. J Antimicrob Chemother 1987;19:848–849.

    Article  PubMed  CAS  Google Scholar 

  47. Jaehde U, Sorgel F, Stephan U, Schunack W. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother 1994;38:1129–1133.

    PubMed  CAS  Google Scholar 

  48. Lazzaroni M, Imbimbo BP, Bargiggia S, et al. Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin. Antimicrob Agents Chemother 1993;37:2212–2216.

    PubMed  CAS  Google Scholar 

  49. Granneman GR, Stephan U, Birner B, et al. Effect of antacid medication on the pharmacokinetics of temafloxacin. Clin Pharmacokinet 1992;22(suppl 1):83–89.

    Article  PubMed  CAS  Google Scholar 

  50. Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1997;39(suppl B):93–97.

    Article  PubMed  CAS  Google Scholar 

  51. Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox® on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy 1999;45:504–511.

    Article  PubMed  CAS  Google Scholar 

  52. Nix DE, Watson WA, Handy L, et al. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy 1989;9:377–380.

    PubMed  CAS  Google Scholar 

  53. Garrelts JC, Godley PJ, Peterie JD, et al. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother 1990;34:931–933.

    PubMed  CAS  Google Scholar 

  54. Van Slooten AD, Nix DE, Wilton JH, Love JH, Spivey JM, Goldstein HR. Combined use of ciprofloxacin and sucralfate. DICP Ann Pharmacother 1991;25:578–582.

    Google Scholar 

  55. Ryerson B, Toothaker R, Schleyer I, Sedman A, Colburn W. Effect of sucralfate on enoxacin pharmacokinetics. Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, September, 1989. Abstract 214.

    Google Scholar 

  56. Lubowski TJ, Nightingale CH, Sweeney K, Quintiliani R. Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. Antimicrob Agents Chemother 1992;36:2758–2760.

    PubMed  CAS  Google Scholar 

  57. Lee L-J, Hafkin B, Lee I-D, Hoh J, Dix R. Effects of food and sucralfate on a single oral dose of 500 mg of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41:2196–2200.

    PubMed  CAS  Google Scholar 

  58. Nix D, Schentag J. Lomefloxacin (L) absorption kinetics when administered with ranitidine (R) and sucralfate (S). Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, September, 1989. Abstract 1276.

    Google Scholar 

  59. Stass H, Schuhly U, Moller JG, Delesen H. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone. Clin Pharmacokinet 2001;40(suppl 1):49–55.

    Article  PubMed  CAS  Google Scholar 

  60. Lehto P, Kivisto KT. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother 1994;38:248–251.

    PubMed  CAS  Google Scholar 

  61. Parpia SH, Nix DE, Hejmanowski LG, et al. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 1989;33:99–102.

    PubMed  CAS  Google Scholar 

  62. Kawakami J, Matsuse T, Kotaki H, et al. The effect of food on the interaction of ofloxacin with sucralfate in healthy volunteers. Eur J Clin Pharmacol 1994;47:67–69.

    Article  PubMed  CAS  Google Scholar 

  63. Zix JA, Geerdes-Fenge HF, Rau M, et al. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother 1997;41:1668–1672.

    PubMed  CAS  Google Scholar 

  64. Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S. The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin. Br J Clin Pharmacol 2000;49:98–103.

    Article  PubMed  CAS  Google Scholar 

  65. Golper T, Hartstein AI, Morthland VH, Christensen JM. Effects of antacids and dialysate dwell times on multiple dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1987;31:1787–1790.

    PubMed  CAS  Google Scholar 

  66. Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Ciprofloxacin and antacids [letter]. Lancet 1986;2:48.

    Article  PubMed  CAS  Google Scholar 

  67. Tuncel T, Bergisadi N. In vitro adsorption of ciprofloxacin hydrochloride on various antacids. Pharmazie 1992;47:304–305.

    Google Scholar 

  68. Wallis SC, Charles BG, Gahan LR, Filippich LJ, Bredhauer MG, Duckworth PA. Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. J Pharm Sci 1996;85:803–809.

    Article  PubMed  CAS  Google Scholar 

  69. Ross DL, Elkington SK, Knaub SR, Riley CM. Physicochemical properties of the fluoroquinolone antimicrobials VI. Effect of metal-ion complexation on octan-1-ol-water partitioning. Int J Pharmaceutics 1993;93:131–138.

    Article  CAS  Google Scholar 

  70. Ross DL, Riley CM. Physicochemical properties of the fluoroquinolone antimicrobials V. Effect of fluoroquinolone structure and pH on the complexation of various fluoroquinolones with magnesium and calcium. Int J Pharmaceutics 1993;93:121–129.

    Article  CAS  Google Scholar 

  71. Ross DL, Riley CM. Physicochemical properties of the fluoroquinolone antimicrobials III. complexation of lomefloxacin with various metal ions and the effect of metal ion complexation on aqueous solubility. Int J Pharmaceutics 1992;87:203–213.

    Article  CAS  Google Scholar 

  72. Helena M, Teixeira SF, Vilas-Boas LS, Gil VMS, Teixeira F. Complexes of ciprofloxacin with metal ions contained in antacid drugs. J Chemother 1995;7:126–132.

    CAS  Google Scholar 

  73. Sonia Rodriguez Cruz M, Gonzalez Alonso I, Sanchez-Navarro A, Luisa Sayalero Marinero M. In vitro study of the interaction between quinolones and polyvalent cations. Pharm Acta Helv 1999;73:237–245.

    Article  Google Scholar 

  74. Hoffken G, Lode H, Wiley P D, et al. Pharmacokinetics and interaction in the bioavailability of new quinolones. Proceedings of the International Symposium of the New Quinolones, Geneva, Switzerland, July, 1986. Abstract 141.

    Google Scholar 

  75. Sorgel F, Seelmann R, Granneman G R, Locke C. Effect of cimetidine on the pharmacokinetics of temafloxacin. Clin Pharmacokinet 1992;22(suppl 1):75–82.

    Article  PubMed  Google Scholar 

  76. Wingender W, Foerster D, Beermann D, et al. Effect of gastric emptying time on rate and extent of the systemic availability of ciprofloxacin. Proceedings of the 14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985. Abstract P-37-91.

    Google Scholar 

  77. Sorgel F, Mahr G, Uwe Koch H, Stephan U, Wiesemann HG, Malter U. Effects of cimetidine on the pharmacokinetics of pefloxacin in healthy volunteers. Rev Infect Dis 1988;10(suppl 1):S137.

    Google Scholar 

  78. Misiak PM, Eldon MA, Toothaker RD, Sedman AJ. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin. J Clin Pharmacol 1993;33:53–56.

    PubMed  CAS  Google Scholar 

  79. Levofloxacin. Data on file (protocol HR 355/1/GB/101). Raritan, NJ: RW Johnson Pharmaceutical Research Institute.

    Google Scholar 

  80. Ludwig E, Graber H, Szekely E, Csiba A. Metabolic interactions of ciprofloxacin. Diagn Microbiol Infect Dis 1990;13:135–141.

    Article  PubMed  CAS  Google Scholar 

  81. Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption. Clin Pharmacol Ther 1992;52:252–256.

    Article  PubMed  CAS  Google Scholar 

  82. Efthymiopoulos C, Bramer SL, Maroli A. Effect of food and gastric pH on the bioavailability of grepafloxacin. Clin Pharmcokinet 1997;33(suppl 1):18–24.

    Article  CAS  Google Scholar 

  83. Gries JM, Honorato J, Taburet AM, et al. Cimetidine does not alter sparfloxacin pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 1995;33:585–587.

    CAS  Google Scholar 

  84. Perry CM, Barman Balfour JA, Lamb HM. Gatifloxacin. Drugs 1999;58:683–696.

    Article  PubMed  CAS  Google Scholar 

  85. Stass HH, Ochmann K. Study to evaluate the interaction between BAY 12-8039 and ranitidine. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June–July, 1997. Abstract 3357.

    Google Scholar 

  86. Stuht H, Lode H, Koeppe P, Rost KL, Schaberg T. Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother 1995;39:1045–1049.

    PubMed  CAS  Google Scholar 

  87. Allen A, Vousden M, Lewis A. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Chemotherapy 1999;45:496–503.

    Article  PubMed  CAS  Google Scholar 

  88. Nix DE, Lebsack ME, Chapelsky M, Sedman AJ, Busch J, Norman A. Effect of oral antacids on disposition of intravenous enoxacin. Antimicrob Agents Chemother 1993;37:775–777.

    PubMed  CAS  Google Scholar 

  89. Yuk JH, Nightingale CH, Sweeney KR, et al. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother 1989;33:1118–1120.

    PubMed  CAS  Google Scholar 

  90. Lubowski TJ, Nightingale CH, Sweeney K, Quintiliani R. The relative bioavailability of temafloxacin administered through a nasogastric tube with and without enteral feeding. Clin Pharmacokinet 1992;22(suppl 1):43–47.

    Article  PubMed  CAS  Google Scholar 

  91. Noer BL, Angaran DM. The effect of enteral feedings on ciprofloxacin pharmacokinetics. Pharmacotherapy 1990;10:254. Abstract 154.

    Google Scholar 

  92. Healy DP, Brodbeck MC, Clendenning CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 1996;40:6–10.

    PubMed  CAS  Google Scholar 

  93. Mueller BA, Brierton DG, Abel SR, Bowman L. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994;38:2101–2105.

    PubMed  CAS  Google Scholar 

  94. Dudley MN, Marchbanks CR, Flor SC, Beals S. The effect of food or milk on the absorption kinetics of ofloxacin. Eur J Clin Pharmacol 1991;41:569–571.

    Article  PubMed  CAS  Google Scholar 

  95. Neuvonen PJ, Kivisto KT. Milk and yoghurt do not impair the absorption of ofloxacin. Br J Clin Pharmacol 1992;33:346–348.

    PubMed  CAS  Google Scholar 

  96. Hoogkamer JFW, Kleinbloesem CH. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers. Drugs 1995;49(suppl 2):346–348.

    Article  PubMed  CAS  Google Scholar 

  97. Lehto P, Kivisto KT. Effects of milk and food on the absorption of enoxacin. Br J Clin Pharmacol 1995;39:194–196.

    PubMed  CAS  Google Scholar 

  98. Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001;40(suppl 1):33–38.

    Article  PubMed  CAS  Google Scholar 

  99. Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther 1991;50:498–502.

    Article  PubMed  CAS  Google Scholar 

  100. Kivisto KT, Ojala-Karlsson P, Neuvonen PJ. Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother 1992;36:489–491.

    PubMed  CAS  Google Scholar 

  101. Stutman HR, Parker KM, Marks MI. Potential of moxalactam and other new antimicrobial agents of bilirubin-albumin displacement in neonates. Pediatrics 1985;75:294–298.

    PubMed  CAS  Google Scholar 

  102. Graber H, Ludwig E, Magyar T, Csiba A, Szekely E. Ofloxacin does not influence antipyrine metabolism. Rev Infect Dis 1989;11(suppl 5):S1093–S1094.

    Google Scholar 

  103. Ludwig E, Graber H, Szekely E, Csiba A. Effect of ciprofloxacin on antipyrine metabolism. Rev Infect Dis 1989;11(suppl 5):S1100–S1101.

    Google Scholar 

  104. Ludwig E, Szekely E, Csiba A, Graber H. The effect of ciprofloxacin on antipyrine metabolism. J Antimicrob Chemother 1988;22:61–67.

    Article  PubMed  CAS  Google Scholar 

  105. Rybak MJ, Bowles SK, Chandrasekar PH, Edwards DJ. Increased theophylline concentrations secondary to ciprofloxacin. Drug Intell Clin Pharm 1987;21:879–881.

    PubMed  CAS  Google Scholar 

  106. Duraski RM. Ciprofloxacin-induced theophylline toxicity [letter]. South Med J 1988;81:1206.

    PubMed  CAS  Google Scholar 

  107. Paidipaty B, Erickson S. Ciprofloxacin-theophylline drug interaction [letter]. Crit Care Med 1990;18:685–686.

    PubMed  CAS  Google Scholar 

  108. Holden R. Probable fatal interaction between ciprofloxacin and theophylline [letter]. Br Med J 1988;297:1339.

    Article  CAS  Google Scholar 

  109. Bem JL, Mann RD. Danger of interaction between ciprofloxacin and theophylline [letter]. Br Med J 1988;296:1131.

    Article  CAS  Google Scholar 

  110. Spivey JM, Laughlin PH, Goss TF, Nix DE. Theophylline toxicity secondary to ciprofloxacin administration. Ann Emerg Med 1991;20:1131–1134.

    Article  PubMed  CAS  Google Scholar 

  111. Thomson AH, Thomson GD, Hepburn M, Whiting B. A clinically significant interaction between ciprofloxacin and theophylline. Eur J Clin Pharmacol 1987;33:435–436.

    Article  PubMed  CAS  Google Scholar 

  112. Rogge MC, Solomon WR, Sedman AJ, et al. The theophylline-enoxacin interaction: II. changes in disposition of theophylline and its metabolites during intermittent administration of enoxacin. Clin Pharmacol Ther 1989;46:420–428.

    Article  PubMed  CAS  Google Scholar 

  113. Davis RL, Kelly HW, Quenzer RW, et al. Effect of norfloxacin on theophylline metabolism. Antimicrob Agents Chemother 1989;33:212–214.

    PubMed  CAS  Google Scholar 

  114. Bowles SK, Popovski Z, Rybak MJ, et al. Effect of norfloxacin on theophylline pharmacokinetics at steady state. Antimicrob Agents Chemother 1988;32:510–512.

    PubMed  CAS  Google Scholar 

  115. Schwartz J, Jauregui L, Lettieri J, Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. Antimicrob Agents Chemother 1988;32:75–77.

    PubMed  CAS  Google Scholar 

  116. Gregoire SL, Grasela TH Jr, Freer JP, et al. Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects. Antimicrob Agents Chemother 1987;31:375–378.

    PubMed  CAS  Google Scholar 

  117. Ho G, Tierney MG, Dales RE. Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline. Clin Pharmacol Ther 1988;44:35–38.

    Article  PubMed  CAS  Google Scholar 

  118. Nix DE, Norman A, Schentag JJ. Effect of lomefloxacin on theophylline pharmacokinetics. Antimicrob Agents Chemother 1989;33:1006–1008.

    PubMed  CAS  Google Scholar 

  119. Rogge MC, Solomon WR, Sedman AJ, et al. The theophylline-enoxacin interaction: I. effect of enoxacin dose size on theophylline disposition. Clin Pharmacol Ther 1988;44:579–587.

    Article  PubMed  CAS  Google Scholar 

  120. Sorgel F, Mahr G, Granneman R, Stephan U. Effects of two quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics. Clin Pharmacokinet 1992;22(suppl 1):65–74.

    Article  PubMed  Google Scholar 

  121. Wijnands WJA, Vree TB, van Herwaarden CLA. Enoxacin decreases the clearance of theophylline in man. Br J Clin Pharmacol 1985;20:583–588.

    PubMed  CAS  Google Scholar 

  122. Takagi K, Hasegawa T, Ogura Y, et al. Comparative studies on interaction between theophylline and quinolones. J Asthma 1988;25:63–71.

    Article  PubMed  CAS  Google Scholar 

  123. Wijnands WJA, Vree TB, van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986;22:677–683.

    PubMed  CAS  Google Scholar 

  124. Sano M, Yamamoto I, Ueda J, et al. Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration. Eur J Clin Pharmacol 1987;32:431–432.

    Article  PubMed  CAS  Google Scholar 

  125. Kinzig-Schippers M, Fuhr U, Cesana M, et al. Absence of effect of rufloxacin on theophylline pharmacokinetics in steady-state. Antimicrob Agents Chemother 1998;42:2359–2364.

    PubMed  CAS  Google Scholar 

  126. Takagi K, Yamaki K, Nadai M, Kuzuya T, Hasegawa T. Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. Antimicrob Agents Chemother 1991;35:1137–1141.

    PubMed  CAS  Google Scholar 

  127. Sano M, Kawakatsu K, Ohkita C, et al. Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans. Eur J Clin Pharmacol 1988;35:161–165.

    Article  PubMed  CAS  Google Scholar 

  128. Robson RA, Begg EJ, Atkinson HC, Saunders CA, Frampton CM. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. Br J Clin Pharmacol 1990;29:491–493.

    PubMed  CAS  Google Scholar 

  129. LeBel M, Vallee F, St. Laurent M. Influence of lomefloxacin on the pharmcokinetics of theophylline. Antimicrob Agents Chemother 1990;34:1254–1256.

    PubMed  CAS  Google Scholar 

  130. Seelmann R, Mahr G, Gottschalk B, Stephan U, Sorgel F. Influence of fleroxacin on the pharmacokinetics of theophylline. Rev Infect Dis 1989;11(suppl 5):S1100.

    Google Scholar 

  131. Soejima R, Niki Y, Sumi M. Effect of fleroxacin on serum concentrations of theophylline. Rev Infect Dis 1989;11(suppl 5):S1099.

    Google Scholar 

  132. Beckman J, Elsasser W, Gundert-Remy U, Hertrampf R. Enoxacin-a potent inhibitor of theophylline metabolism. Eur J Clin Pharmacol 1987;33:227–230.

    Article  Google Scholar 

  133. Wijnands WJA, Cornel JH, Martea M, Vree TB. The effect of multiple dose oral lomefloxacin on theophylline metabolism in man. Chest 1990;98:1440–1444.

    Article  PubMed  CAS  Google Scholar 

  134. Niki Y, Soejima R, Kawane H, et al. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest 1987;92:663–669.

    Article  PubMed  CAS  Google Scholar 

  135. Wijnands WJA, van Herwaarden CLA, Vree TB. Enoxacin raises plasma theophylline concentrations [letter]. Lancet 1984;2:108–109.

    Article  PubMed  CAS  Google Scholar 

  136. Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. Am J Med 1987;82(suppl 4A):115–118.

    PubMed  CAS  Google Scholar 

  137. Gisclon LG, Curtin CR, Fowler CL, Nayak RK. Absence of pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1995. Abstract A39.

    Google Scholar 

  138. Dickens GR, Wermeling D, Vincent J. Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men. J Clin Pharmacol 1997;37:248–252.

    PubMed  CAS  Google Scholar 

  139. Vincent J, Teng R, Dogolo L C, Willavize S A, Friedman H L. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother 1997;39(suppl B):81–86.

    Article  PubMed  CAS  Google Scholar 

  140. Fourtillan J B, Granier J, Saint-Salvi B, et al. Pharmacokinetics of ofloxacin and theophylline alone and in combination. Infection 1986;14(suppl 1):S67–S69.

    Article  PubMed  CAS  Google Scholar 

  141. Batty KT, Davis TME, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995;39:305–311.

    PubMed  CAS  Google Scholar 

  142. Efthymiopoulos C, Bramer SL, Maroli A, Blum B. Theophylline and warfarin interaction studies with grapafloxacin. Clin Pharmacokinet 1997;33(suppl 1):39–46.

    Article  PubMed  CAS  Google Scholar 

  143. Niki Y, Hashiguchi K, Miyashita N, Nakajima M, Matsushima T, Soejima R. Effects of AM-1155 on serum concentration of theophylline. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September, 1996, Abstract F73.

    Google Scholar 

  144. Stass HH, Kubitza D, Schweitert H, Wemer R. BAY 12-8039 does not interact with theophylline. Proceedings of the 20th International Congress of Chemotherapy, Sydney, Australia, June–July, 1997. Abstract 3356.

    Google Scholar 

  145. Stass H, Kubitza D. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Clin Pharmacokinet 2001;40(suppl 1):63–70.

    Article  PubMed  CAS  Google Scholar 

  146. Davy M, Allen A, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. Chemotherapy 1999;45:478–484.

    Article  PubMed  CAS  Google Scholar 

  147. Kinzig-Schippers M, Fuhr U, Zaigler M, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP 1A2. Clin Pharmacol Ther 1999;65:262–274.

    Article  PubMed  CAS  Google Scholar 

  148. Carbo M, Segura J, de la Torre R, et al. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 1989;45:234–240.

    Article  PubMed  CAS  Google Scholar 

  149. Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989;33:474–478.

    PubMed  CAS  Google Scholar 

  150. Mahr G, Sorgel F, Granneman R, et al. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet 1992;22(suppl 1):90–97.

    Article  PubMed  CAS  Google Scholar 

  151. Harder S, Staib AH, Beer C, et al. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 1988;35:651–656.

    Article  PubMed  CAS  Google Scholar 

  152. Peloquin CA, Nix DE, Sedman AJ, et al. Pharmacokinetics and clinical effects of caffeine alone and in combination with oral enoxacin. Rev Infect Dis 1989;11(suppl 5):S1095.

    Google Scholar 

  153. Stille W, Harder S, Mieke S, et al. Decrease of caffeine elimination in man during coadministration of 4-quinolones. J Antimicrob Chemother 1987;20:729–734.

    Article  PubMed  CAS  Google Scholar 

  154. Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother 1990;26(suppl D):7–29.

    PubMed  CAS  Google Scholar 

  155. Healy DP, Schoenle JR, Stotka J, Polk RE. Lack of interaction between lomefloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1991;35:660–664.

    PubMed  CAS  Google Scholar 

  156. LeBel M, Teng R, Dogolo LC, Willavize S, Friedman HL, Vincent J. The effect of steadystate trovafloxacin on the steady-state pharmacokinetics of caffeine in healthy subjects. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September, 1996. Abstract A1.

    Google Scholar 

  157. Stahlberg HJ, Gohler K, Guillaume M, Mignot A. Effects of gatifloxacin (GTX) on the pharmacokinetics of theophylline in healthy young volunteers. J Antimicrob Chemother 1999;44(suppl A):136. Abstract P435.

    Google Scholar 

  158. Manita S, Toriumi C, Kusajima H, Momo K. The influence of gatifloxacin (AM-1155) on pharmacokinetics and metabolism of theophylline in rats and humans. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September, 1998. Abstract A-16a.

    Google Scholar 

  159. Parent M, LeBel M. Meta-analysis of quinolone-theophylline interactions. DICP Ann Pharmacother 1991;25:191–194.

    CAS  Google Scholar 

  160. Barnett G, Segura J, de la Torre R, Carbo M. Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition. Eur J Clin Pharmcol 1990;39:63–69.

    Article  CAS  Google Scholar 

  161. Toon S, Hopkins KJ, Garstang FM, et al. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987;42:33–41.

    Article  PubMed  Google Scholar 

  162. Millar E, Coles S, Wyld P, Nimmo W. Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects. Clin Pharmacokinet 1992;22(suppl 1):102–106.

    Article  PubMed  CAS  Google Scholar 

  163. Rindone JP, Keuey CL, Jones WN, Garewal HS. Hypoprothrombinemic effect of warfarin is not influenced by ciprofloxacin. Clin Pharm 1991;10:136–138.

    PubMed  CAS  Google Scholar 

  164. Rocci ML Jr, Vlasses PH, Dislerath LM, et al. Norfloxacin does not alter warfarin’s disposition or anticoagulant effect. J Clin Pharmacol 1990;30:728–732.

    PubMed  Google Scholar 

  165. Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YWJ. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy 1992;12:435–439.

    PubMed  CAS  Google Scholar 

  166. Israel DS, Stotka JL, Rock W, et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis 1996;22:251–256.

    PubMed  CAS  Google Scholar 

  167. Levofloxacin. Data on file (protocol LOFBO-PH10-098). Raritan, NJ: RW Johnson Pharmaceutical Research Institute.

    Google Scholar 

  168. Teng R, Apseloff G, Vincent J, Pelletier SM, Willavize AS, Friedman HL. Effect of trovafloxacin (CP-99,129) on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September, 1996. Abstract A2.

    Google Scholar 

  169. Muller FO, Hundt HKL, Muir AR, et al. Study to investigate the influence of 400 mg BAY 12-8039 (M) given once daily to healthy volunteers on PK and PD of warfarin (W). Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September, 1998. Abstract A13.

    Google Scholar 

  170. Sparfloxacin (Zagam®) [package insert]. Research Triangle Park, NC: Bertek Pharmaceuticals, February 2003.

    Google Scholar 

  171. Davy M, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Chemotherapy 1999;45:491–495.

    Article  PubMed  CAS  Google Scholar 

  172. Jolson HM, Tanner LA, Green L, Grasela TH Jr. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med 1991;151:1003–1004.

    Article  PubMed  CAS  Google Scholar 

  173. Kamada A. Possible interaction between ciprofloxacin and warfarin. DICP Ann Pharmacother 1990;24:27–28.

    CAS  Google Scholar 

  174. Leor J, Matetzki S. Ofloxacin and warfarin [letter]. Ann Intern Med 1988;109:761.

    PubMed  CAS  Google Scholar 

  175. Linville D, Emory C, Graves L. Ciprofloxacin and warfarin interaction [letter]. Am J Med 1991;90:765.

    Article  PubMed  Google Scholar 

  176. Linnville T, Matanin D. Norfloxacin and warfarin [letter]. Ann Intern Med 1989;110;751–752.

    Google Scholar 

  177. Mott FE, Murphy S, Hunt V. Ciprofloxacin and warfarin [letter]. Ann Intern Med 1989;111:542–543

    PubMed  CAS  Google Scholar 

  178. Dugoni-Kramer BM. Ciprofloxacin-warfarin interaction [letter]. DICP Ann Pharmacother 1991;25:1397.

    CAS  Google Scholar 

  179. Renzi R, Finkbeiner S. Ciprofloxacin interaction with sodium warfarin. Am J Emerg Med 1991;9:551–552.

    Article  PubMed  CAS  Google Scholar 

  180. Ravnan SL, Locke C. Levofloxacin and warfarin interaction. Pharmacotherapy 2001;21:884–885.

    Article  PubMed  CAS  Google Scholar 

  181. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000;63:28–31.

    Article  PubMed  CAS  Google Scholar 

  182. Jones CB, Fugate SE. Levofloxacin and warfarin interaction. Ann Pharmacother 2002;36:1554–1557.

    Article  PubMed  Google Scholar 

  183. Artymowicz RJ, Cino BJ, Rossi JG, Walker JL, Moore S. Possible interaction between gatifloxacin and warfarin [letter]. Am J Health-Sys Pharm 2002;59:1205–1206.

    Google Scholar 

  184. Byrd DC, Gaskins SE, Parrish AM, Freeman LB. Warfarin and ciprofloxacin interaction: case report and controversy. J Am Board Fam Pract 1999;12:486–488.

    PubMed  CAS  Google Scholar 

  185. Anonymous. Fluoroquinolones and warfarin: suspected interactions. Can Fam Physician 2004;50:1417.

    Google Scholar 

  186. Mant T, Morrison P, Millar E. Absence of drug interaction between temafloxacin and low dose heparin. Clin Pharmacokinet 1992;22(suppl 1):98–101.

    Article  PubMed  CAS  Google Scholar 

  187. Avent CK, Krinsky D, Kirklin JK, et al. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. Am J Med 1988;85:452–453.

    Article  PubMed  CAS  Google Scholar 

  188. Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporin A [letter]. J Antimicrob Chemother 1988;21:679–680.

    Article  PubMed  CAS  Google Scholar 

  189. Thomson DJ, Menkis AH, McKenzie FN. Norfloxacin-cyclosporine interaction. Transplantation 1988;46:312–313.

    Article  PubMed  CAS  Google Scholar 

  190. Nasir M, Rotellar C, Hand M, Kulczycki L, Alijani MR, Winchester JF. Interaction between ciclosporin and ciprofloxacin [letter]. Nephron 1991;57:245–246.

    Article  PubMed  CAS  Google Scholar 

  191. McLellan R, Drobitch RK, McLellan H, Acott PD, Crocker JFS, Renton KW. Norfloxacin interferes with cyclosporin disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995;58:322–327.

    Article  PubMed  CAS  Google Scholar 

  192. Kruger HU, Schuler U, Proksch B, et al. Investigations of potential interaction between ciprofloxacin and cyclosporin A in patients with renal transplants. Antimicrob Agents Chemother 1990;34:1048–1052.

    PubMed  CAS  Google Scholar 

  193. Lang J, de Villaine FJ, Guemi A, et al. Absence of pharmacokinetic interaction between pefloxacin and cyclosporin A in patients with renal transplants. Rev Infect Dis 1989;11(suppl 5):S1094.

    Google Scholar 

  194. Lang J, de Villaine FJ, Garraffo R, Touraine J-L. Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving ciprofloxacin. Am J Med 1989;87(suppl 5A):82S–85S.

    Article  PubMed  CAS  Google Scholar 

  195. Pichard L, Fabre I, Fabre G, et al. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595–606.

    PubMed  CAS  Google Scholar 

  196. Robinson JA, Venezio FR, Costanzo-Nordin MR, et al. Patients receiving quinolones and cyclosporin after heart transplantation. J Heart Transplant 1990;9:30–31.

    PubMed  CAS  Google Scholar 

  197. Tan KKC, Trull AK, Shawket S. Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction. Br J Clin Pharmacol 1989;28:185–187.

    PubMed  CAS  Google Scholar 

  198. Hooper TL, Gould FK, Swinburn CR, et al. Ciprofloxacin: a preferred treatment for legionella infections in patients receiving cyclosporin A [letter]. J Antimicrob Chemother 1988;22:952–953.

    Article  PubMed  CAS  Google Scholar 

  199. Van Buren DH, Koestner J, Adedoyin A, et al. Effect of ciprofloxacin on cyclosporine pharmacokinetics. Transplantation 1990;50:888–889.

    PubMed  Google Scholar 

  200. Levofloxacin. Data on file (protocol N93-059). Raritan, NJ: RW Johnson Pharmaceutical Research Institute.

    Google Scholar 

  201. Capone D, Carrano R, Gentile A, et al. Pharmacokinetic interaction between tacrolimus and levofloxacin in kidney transplant recipients [abstract]. Nephrol Dial Transpl 2001;16:A207.

    Google Scholar 

  202. Olsen SJ, Uderman HD, Kaul S, Kollia GD, Birkhofer MJ, Grasela DM. Pharmacokinetics (PK) of concomitantly administered gatifloxacin and digoxin. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1999. Abstract 199.

    Google Scholar 

  203. Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001;32(suppl 1):S47–S50.

    Article  PubMed  CAS  Google Scholar 

  204. Vouden M, Allen A, Lewis A, Ehren N. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers. Chemotherapy 1999;45:485–490.

    Article  Google Scholar 

  205. Chien S-C, Rogge MC, Williams RR, Natarajan J, Wong F, Chow AT. Absence of a pharmacokinetic interaction between digoxin and levofloxacin. J Clin Pharm Ther 2002;27:7–12.

    Article  PubMed  CAS  Google Scholar 

  206. Johnson RD, Dorr MB, Hunt TL, Conway S, Talbot GH. Pharmacokinetic interaction of sparfloxacin and digoxin. Clin Ther 1999;21:368–379.

    Article  PubMed  CAS  Google Scholar 

  207. Vincent J, Hunt T, Teng R, Robarge L, Willavize SA, Friedman HL. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects. Am J Surg 1998;176(suppl 6A):32S–38S.

    Article  PubMed  CAS  Google Scholar 

  208. Morran C, McArdle C, Pettitt L, et al. Pharmacokinetics of orally administered ciprofloxacin in abdominal surgery. Am J Med 1989;87(suppl 5A):86S–88S.

    Article  PubMed  CAS  Google Scholar 

  209. Grant EM, Zhong MK, Fitzgerald JF, Nicolau DP, Nightingale C, Quintiliani R. Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. J Clin Pharmacol 2001;41:206–209.

    Article  PubMed  CAS  Google Scholar 

  210. Labbe L, Robitaille NM, Lefez C et al. Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man. Ther Drug Monit. 2004;26:492–498.

    Article  PubMed  CAS  Google Scholar 

  211. Kamali F, Thomas SHL, Edwards C. The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. Eur J Clin Pharmacol 1993;44:365–367.

    Article  PubMed  CAS  Google Scholar 

  212. Wijnands WJA, Trooster JFG, Teunissen PC, et al. Ciprofloxacin does not impair the elimination of diazepam in humans. Drug Metab Dispos 1990;18:954–957.

    PubMed  CAS  Google Scholar 

  213. Grasela DM, LaCreta FP, Kollia GD, Randall DM, Uderman HD. Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers. Pharmacotherapy 2000;20:330–335.

    Article  PubMed  CAS  Google Scholar 

  214. Waite NM, Rybak MJ, Krakovsky DJ, et al. Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin. Antimicrob Agents Chemother 1991;35:130–134.

    PubMed  CAS  Google Scholar 

  215. Loi C-M, Parker BM, Cusack BJ, Vestal RE. Aging and drug interactions. III. individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997;280:627–637.

    PubMed  CAS  Google Scholar 

  216. Chandler MHH, Toler SM, Rapp RP, et al. Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. Antimicrob Agents Chemother 1990;34:442–447.

    PubMed  CAS  Google Scholar 

  217. Bernard E, Garraffo R, Leclercq-Boscherel B, Garret C, Bidault R, Dellamonica P. Drug interaction between grepafloxacin (GFX) and rifampin (RIF) in healthy volunteers. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1999. Abstract 6.

    Google Scholar 

  218. Schrenzel J, Dayer P, Leemann T, Weidekamm E, Portmann R, Lew DP. Influence of rifampin on fleroxacin pharmacokinetics. Antimicrob Agents Chemother 1993;37:2132–2138.

    PubMed  CAS  Google Scholar 

  219. Orisakwe OE, Agbasi PU, Afonne OJ, Ofeofule SI, Obi E, Orish CN. Rifampicin pharmacokinetics with and without ciprofloxacin. Am J Ther 2001;8:151–153.

    Article  PubMed  CAS  Google Scholar 

  220. Orisakwe OE, Afonne OJ, Agbasi PU, Ofoefule SI. Urinary excretion of rifampicin in the presence of ciprofloxacin. Am J Ther 2004;11:171–174.

    Article  PubMed  Google Scholar 

  221. Orisakwe OE, Akunyili DN, Agbasi PU, Ezejiofor NA. Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin. Am J Ther 2004;11:283–287.

    Article  PubMed  Google Scholar 

  222. Orisakwe OE, Agbasi PU, Ofoefule SI, et al. Effect of pefloxacin on the urinary excretion of rifampicin. Am J Ther 2004;11:13–16.

    Article  PubMed  Google Scholar 

  223. Markowitz JS, Gill HS, Devane CL, Mintzer JE. Fluoroquinolone inhibition of clozapine metabolism [letter]. Am J Psychiatry 1997;153:881.

    Google Scholar 

  224. Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration [letter]. J Clin Psychopharmacol 1999;19:289–291.

    Article  PubMed  CAS  Google Scholar 

  225. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions [letter]. Lancet 2000;356:2069–2070.

    Article  PubMed  CAS  Google Scholar 

  226. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000;56:585–589.

    Article  PubMed  CAS  Google Scholar 

  227. Dalle J-H, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol 2002;24:321–322.

    Article  PubMed  Google Scholar 

  228. Takahashi H, Higuchi H, Shimizu T. Severe lithium toxicity induced by combined levofloxacin administration [letter]. J Clin Psychiatry 2000;61:949–950.

    Article  PubMed  CAS  Google Scholar 

  229. Scholten PC, Droppert RM, Zwinkels MGJ, Moesker HL, Nauta JJP, Hoepelman IM. No interaction between ciprofloxacin and an oral contraceptive. Antimicrob Agents Chemother 1998;42:3266–3268.

    PubMed  CAS  Google Scholar 

  230. Chien SC, Chow AT, Rogge MC, Williams RR, Hendrix CW. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. Antimicrob Agents Chemother 1997;41:1765–1769.

    PubMed  CAS  Google Scholar 

  231. Villani P, Viale P, Signorini L, et al. Pharmacokinetic evaluation of oral levofloxacin in human immmunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy. Antimicrob Agents Chemother 2001;45:2160–2162.

    Article  PubMed  CAS  Google Scholar 

  232. Ofoefule SI, Obodo CE, Orisakwe OE, et al. Some plasma pharmacokinetic parameters of isoniazid in the presence of a fluoroquinolone antibacterial agent. Am J Ther 2001;8:243–246.

    Article  PubMed  CAS  Google Scholar 

  233. Ofoefule SI, Obodo CE, Orisakwe OE, et al. Salivary and urinary excretion and plasmasaliva concentration ratios of isoniazid in the presence of co-administered ciprofloxacin. Am J Ther 2002;9:15–18.

    Article  PubMed  Google Scholar 

  234. Kamali F. No influence of ciprofloxacin on ethanol disposition. Eur J Clin Pharmacol 1994;47:71–74.

    Article  PubMed  CAS  Google Scholar 

  235. Tillonen J, Homann N, Rautio M, Jousimies-Somer H, Salaspuro M. Ciprofloxacin decreases the rate of ethanol elimination in humans. Gut 1999;44:347–352.

    Article  PubMed  CAS  Google Scholar 

  236. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 2003;58:653–657.

    PubMed  CAS  Google Scholar 

  237. Risk of serious seizures from concomitant use of ciprofloxacin and phenytoin in patients with epilepsy. CMAJ 1998;158:104–105.

    Google Scholar 

  238. Hull RL. Possible phenytoin-ciprofloxacin interaction [letter]. Ann Pharmacother 1993;27:1283.

    PubMed  CAS  Google Scholar 

  239. Pollak PT, Slayter KL. Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin. Ann Pharmacother 1997;31:61–64.

    PubMed  CAS  Google Scholar 

  240. Dillard ML, Fink RM, Parkerson R. Ciprofloxacin-phenytoin interaction [letter]. Ann Pharmacother 1992;26:263.

    PubMed  CAS  Google Scholar 

  241. Brouwers PJ, DeBoer LE, Guchelaar H-J. Ciprofloxacin-phenytoin interaction [letter]. Ann Pharmacother 1997;31:498.

    PubMed  CAS  Google Scholar 

  242. Otero M-J, Moran D, Valverde M-P, Dominguez-Gil A. Interaction between phenytoin and ciprofloxacin [letter]. Ann Pharmacother 1999;33:251–252.

    Article  PubMed  CAS  Google Scholar 

  243. Job ML, Arn SK, Strom JG, Jacobs NF, D’Souza MJ. Effect of ciprofloxacin on the pharmacokinetics of multiple-dose phenytoin serum concentrations. Ther Drug Monitor 1994;16:427–431.

    Article  CAS  Google Scholar 

  244. Davis RL, Quenzer RW, Kelly HW, Powell JR. Effect of the addition of ciprofloxacin on theophylline pharmacokinetics in subjects inhibited by cimetidine. Ann Pharmcother 1992;26:11–13.

    CAS  Google Scholar 

  245. Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE. Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 1996;40:1715–1716.

    PubMed  CAS  Google Scholar 

  246. Loi C-M, Parker BM, Cusack BJ, Vestal RE. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br J Clin Pharmacol 1993;36:195–200.

    PubMed  CAS  Google Scholar 

  247. Hasegawa T, Nadai M, Kuzuya T, et al. The possible mechanism of interaction between xanthines and quinolone. J Pharm Pharmacol 1990;42:767–772.

    PubMed  CAS  Google Scholar 

  248. Fuhr U, Strobl G, Manaut F, et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P-450 isoform CYP1A2. Mol Pharmacol 1993;43:191–199.

    PubMed  CAS  Google Scholar 

  249. Fuhr U, Anders E-M, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P-450 1A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992;36:942–948.

    PubMed  CAS  Google Scholar 

  250. Sarkar M, Polk RE, Guzelian PS, Hunt C, Karnes HT. In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob Agents Chemother 1990;34:594–599.

    PubMed  CAS  Google Scholar 

  251. Wingender W, Beerman D, Foerster D, et al. Mechanism of renal excretion of ciprofloxacin, a new quinolone carboxylic acid derivative in humans. Chemioterapia 1985;4(suppl 2):403–404.

    Google Scholar 

  252. Levofloxacin. Data on file (protocol HR355/1/GB/101). Raritan, NJ: RW Johnson Pharmaceutical Research Institute.

    Google Scholar 

  253. Shimada J, Yamaji T, Ueda Y, Uchida H, Kusajima H, Irikura T. Mechanism of renal excretion of AM-715, a new quinolone carboxylic acid derivative, in rabbits, dogs, and humans. Antimicrob Agents Chemother 1983;23:1–7.

    PubMed  CAS  Google Scholar 

  254. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 1995;58:532–541.

    Article  PubMed  CAS  Google Scholar 

  255. Nakashima M, Uematsu T, Kosuge K, et al. Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995;39:2635–2640.

    PubMed  CAS  Google Scholar 

  256. Stass H, Sachse R. Effect of probenecid on the kinetics of a single oral 400 mg dose of moxifloxacin in healthy volunteers. Clin Pharmacokinet 2001;40(suppl 1):71–76.

    Article  PubMed  CAS  Google Scholar 

  257. Sudoh T, Fujimura A, Shiga T, et al. Renal clearance of lomefloxacin is decreased by furosemide. Eur J Clin Pharmacol 1994;46:267–269.

    Article  PubMed  CAS  Google Scholar 

  258. Sudoh T, Fujimura A, Harada K, Sunaga K, Ohmori M, Sakamoto K. Effect of ranitidine on renal clearance of lomefloxacin. Eur J Clin Pharmacol 1996;51:95–98.

    Article  PubMed  CAS  Google Scholar 

  259. Martin DE, Shen J, Griener J, Raasch R, Patterson JH, Cascio W. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. J Clin Pharmacol 1996;36:85–91.

    PubMed  CAS  Google Scholar 

  260. Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004;48:4766–4777.

    Article  PubMed  CAS  Google Scholar 

  261. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 1990;26(suppl B):219–225.

    PubMed  CAS  Google Scholar 

  262. Anastasio GD, Menscer D, Little JM Jr. Norfloxacin and seizures [letter]. Ann Intern Med 1988;109:169–170.

    PubMed  CAS  Google Scholar 

  263. Lucet J-C, Tilly H, Lerebours G, Gres J-J, Piguet H. Neurological toxicity related to pefloxacin [letter]. J Antimicrob Chemother 1988;21:811–812.

    Article  PubMed  CAS  Google Scholar 

  264. Rollof J, Vinge E. Neurologic adverse effects during concomitant treatment with ciprofloxacin, NSAIDs, and chloroquine: possible drug interaction. Ann Pharmacother 1993;27:1058–1059.

    PubMed  CAS  Google Scholar 

  265. Slavich IL, Gleffe RF, Haas EJ. Grand mal epileptic seizures during ciprofloxacin therapy [letter]. JAMA 1989;261:558–559.

    Article  PubMed  CAS  Google Scholar 

  266. Simpson KJ, Brodie MJ. Convulsions related to enoxacin [letter]. Lancet 1985;2:161.

    Article  PubMed  CAS  Google Scholar 

  267. Rumsey S, Wilkinson TJ, Scott SD. Ciprofloxacin-induced seizures—the need for increased vigilance. Aust J Hosp Pharm 1995;25:145–147.

    Google Scholar 

  268. Yamamoto K, Naitoh Y, Inoue Y, et al. Seizure discharges induced by the combination of new quinolone carboxylic acid drugs and non-steroidal anti-inflammatory drugs. Chemotherapy 1988;36(suppl 2):300–324.

    CAS  Google Scholar 

  269. Matsuno K, Kunihiro E, Yamatoya O, et al. Surveillance of adverse reactions due to ciprofloxacin in Japan. Drugs 1995;49(suppl 2):495–496.

    Article  PubMed  CAS  Google Scholar 

  270. Naora K, Katagiri Y, Ichikawa N, Hayashibara M, Iwamoto K. Enhanced entry of ciprofloxacin into the rat central nervous system induced by fenbufen. J Pharmacol Exp Ther 1991;258:1033–1037.

    PubMed  CAS  Google Scholar 

  271. Ichikawa N, Naora K, Hayashibara M, Katagiri Y, Iwamoto K. Effect of fenbufen on the entry of new quinolones, norfloxacin and ofloxacin, into the central nervous system in rats. J Pharm Pharmacol 1992;44:915–920.

    PubMed  CAS  Google Scholar 

  272. Naora K, Katagiri Y, Iwamoto K, Tanaka K, Yamaguchi T, Sekine Y. Effect of fenbufen on the pharmacokinetics of sparfloxacin in rats. J Antimicrob Chemother 1992;30:673–683.

    Article  PubMed  CAS  Google Scholar 

  273. Naora K, Katagiri Y, Ichikawa N, Hayashibara M, Iwamoto K. A possible reduction in the renal clearance of ciprofloxacin by fenbufen in rats. J Pharm Pharmacol 1990;42:704–707.

    PubMed  CAS  Google Scholar 

  274. Katagiri Y, Naora K, Ichikawa N, Hayashibara M, Iwamoto K. Absence of pharmacokinetic interaction between ofloxacin and fenbufen in rats. J Pharm Pharmacol 1989;41:717–719.

    PubMed  CAS  Google Scholar 

  275. Naora K, Katagiri Y, Ichikawa N, Hayashibara M, Iwamoto K. A minor possibility of pharmacokinetic interaction between enoxacin and fenbufen in rats. J Pharmacobio-Dyn 1990;13:90–96.

    PubMed  CAS  Google Scholar 

  276. Kamali F. Lack of a pharmacokinetic interaction between ciprofloxacin and fenbufen. J Clin Pharm Ther 1994;19:257–259.

    Article  PubMed  CAS  Google Scholar 

  277. Fillastre JP, Leroy A, Borsa-Lebas F, Etienne I, Gy C, Humbert G. Lack of effect of ketoprofen on the pharmacokinetics of pefloxacin and ofloxacin [letter]. J Antimicrob Chemother 1993;31:805–806.

    Article  PubMed  CAS  Google Scholar 

  278. Fillastre JP, Leroy A, Borsa-Lebas F, Etienne I, Gy C, Humbert G. Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers. Drugs Exp Clin Res 1992;18:487–492.

    PubMed  CAS  Google Scholar 

  279. Halliwell RF, Lambert JJ, Davey PG. Actions of quinolones and nonsteroidal antiinflammatory drugs on γ-aminobutyric acid currents of rat dorsal root ganglion neurons. Rev Infect Dis 1989;11(suppl 5):S1398–S1399.

    Google Scholar 

  280. Halliwell RF, Davey PG, Lambert JJ. The effects of quinolones and NSAIDs upon GABA-evoked currents recorded from rat dorsal root ganglion neurones. J Antimicrob Chemother 1991;27:209–218.

    Article  PubMed  CAS  Google Scholar 

  281. Akahane K, Sekiguchi M, Une T, Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with γ-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989;33:1704–1708.

    PubMed  CAS  Google Scholar 

  282. Segev S, Rehavi M, Rubinstein E. Quinolones, theophylline, and diclofenac interactions with the γ-aminobutyric acid receptor. Antimicrob Agents Chemother 1988;32:1624–1626.

    PubMed  CAS  Google Scholar 

  283. Hori S, Shimada J, Saito A, Matsuda M, Miyahara T. Comparison of the inhibitory effects of new quinolones on γ-aminobutyric acid receptor binding in the presence of antiinflammatory drugs. Rev Infect Dis 1989;11(suppl 5):S1397–S1398.

    Google Scholar 

  284. Motomura M, Kataoka Y, Takeo G, et al. Hippocampus and frontal cortex are the potential mediatory sites for convulsions induced by new quinolones and non-steroidal anti-inflammatory drugs. Int J Clin Pharmacol Ther Toxicol 1991;29:223–227.

    PubMed  CAS  Google Scholar 

  285. Kawakami J, Shimokawa M, Yamamoto K, et al. Inhibition of GABAA receptor-mediated current responses by enoxacin (new quinolone) and felbinac (non-steroidal antiinflammatory drug) in Xenopus oocytes injected with mouse-brain messenger RNA. Biol Pharm Bull 1993;16:726–728.

    PubMed  CAS  Google Scholar 

  286. Christ W, Gindler K, Gruene S, et al. Interactions of quinolones with opioids and fenbufen, a nonsteroidal antiinflammatory drug: involvement of dopaminergic neurotransmission. Rev Infect Dis 1989;11(suppl 5):S1393–S1394.

    Google Scholar 

  287. Kawakami J, Yamamoto K, Asanuma A, Yanagisawa K, Sawada Y, Iga T. Inhibitory effect of new quinolones on GABAbA receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: correlation with convulsive potency in vivo. Toxicol Appl Pharmacol 1997;145:246–254.

    Article  PubMed  CAS  Google Scholar 

  288. Imanishi T, Akahane K, Akaike N. Attenuated inhibition by levofloxacin, l-isomer of ofloxacin, on GABA response in the dissociated rat hippocampal neurons. Neurosci Lett 1995;193:81–84.

    Article  PubMed  CAS  Google Scholar 

  289. Akahane K, Tsutomi Y, Kimura Y, Kitano Y. Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABA receptor binding. Chemotherapy 1994;40:412–417.

    Article  PubMed  CAS  Google Scholar 

  290. Yakushiji T, Shirasaki T, Akaike N. Non-competitive inhibition of GABAA responses by a new class of quinolones and non-steroidal anti-inflammatories in dissociated frog sensory neurones. Br J Pharmacol 1992;105:13–18.

    PubMed  CAS  Google Scholar 

  291. Halliwell RF, Davey PG, Lambert JJ. A patch clamp study of the effects of ciprofloxacin and biphenyl acetic acid on rat hippocampal neurone GABAA and ionotropic glutamate receptors. Neuropharmacology 1995;34:1615–1624.

    Article  PubMed  CAS  Google Scholar 

  292. Tsuji A, Sato H, Okezaki E, Nagata O, Kato H. Effect of the anti-inflammatory agent fenbufen on the quinolone-induced inhibition of γ-aminobutyric acid binding to rat brain membranes in vitro. Biochem Pharmacol 1988;37:4408–4411.

    Article  PubMed  CAS  Google Scholar 

  293. Ito T, Miura Y, Kadokawa T, Hori S, Shimada J, Migahara T. Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices. Pharmacol Toxicol 1991;68:220–225.

    Article  PubMed  CAS  Google Scholar 

  294. Ito Y, Ishige K, Aizawa M, Fukuda H. Characterization of quinolone antibacterial-induced convulsions and increases in nuclear AP-1 DNA-and CRE-binding activities in mouse brain. Neuropharmacology 1999;38:717–723.

    Article  PubMed  CAS  Google Scholar 

  295. Marchand S, Pariat C, Bouquet S, Courtois P, Couet W. Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. Br J Pharmacol 2000;129:1609–1616.

    Article  PubMed  CAS  Google Scholar 

  296. Marchand S, Pariat C, Boulanger A, Bouquet S, Couet W. A pharmacokinetic/pharmacodynamic approach to show that not all fluoroquinolones exhibit similar sensitivity toward the proconvulsant effect of biphenyl acetic acid in rats. J Antimicrob Chemother 2001;48:813–820.

    Article  PubMed  CAS  Google Scholar 

  297. Smolders I, Gousseau C, Marchand S, Couet W, Ebinger G, Michotte Y. Convulsant and subconvulsant doses of norfloxacin in the presence and absence of biphenylacetic acid alter extracellular hippocampal glutamate but not gamma-aminobutyric acid levels in conscious rats. Antimicrob Agents Chemother 2002;46:471–477.

    Article  PubMed  CAS  Google Scholar 

  298. Kohno K, Niwa M, Nozaki M, et al. Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenylacetic acid. Gen Pharmacol 1997;29:767–770.

    PubMed  CAS  Google Scholar 

  299. Masukawa T, Nakanishi K, Natsuki R, et al. Role of nitric oxide in the convulsions following the coadministration of enoxacin with fenbufen in mice. Jpn J Pharmacol 1998;76:425–429.

    Article  PubMed  CAS  Google Scholar 

  300. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 1996;37(suppl A):161–167.

    PubMed  CAS  Google Scholar 

  301. Demolis JL, Charransol A, Funck-Bretano C, Jaillon P. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 1996;41:499–503.

    Article  PubMed  CAS  Google Scholar 

  302. Morganroth J, Talbot GH, Dorr MB, Johnson RD, Geary W, Magner D. Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin Ther 1999;21:818–828.

    Article  PubMed  CAS  Google Scholar 

  303. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999;28:352–364.

    Article  PubMed  CAS  Google Scholar 

  304. Lode H, Vogel F, Elies W. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Clin Ther 1999;21:61–74.

    Article  PubMed  CAS  Google Scholar 

  305. Springsklee M, Reiter C, Meyer JM. Safety and tolerability profile of moxifloxacin. Proceedings of the 13th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, March, 1999. Abstract P-0208.

    Google Scholar 

  306. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468–1472.

    Article  PubMed  CAS  Google Scholar 

  307. Samaha FF. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin [letter]. Am J Med 1999;107:528–529.

    Article  PubMed  CAS  Google Scholar 

  308. Owens RC Jr, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002;22:663–672.

    Article  PubMed  Google Scholar 

  309. Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002;34:861–863.

    Article  PubMed  Google Scholar 

  310. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004;75:242–247.

    Article  PubMed  CAS  Google Scholar 

  311. Paltoo B, O’Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol 2001;24:895–897.

    Article  PubMed  CAS  Google Scholar 

  312. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001;59:122–126.

    PubMed  CAS  Google Scholar 

  313. Anderson ME, Mazur A, Yang T, Roden DM. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001;296:806–810.

    PubMed  CAS  Google Scholar 

  314. Hagiwara T, Satoh S, Kasai Y, Takasuna K. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol 2001;87:231–234.

    Article  PubMed  CAS  Google Scholar 

  315. Patmore L, Fraser S, Mair D, Templeton A. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur J Pharmacol 2000;406:449–452.

    Article  PubMed  CAS  Google Scholar 

  316. Bischoff U, Schmidt C, Netzer R, Pongs O. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000;406:341–343.

    Article  PubMed  CAS  Google Scholar 

  317. Satoh Y, Sugiyama A, Chiba K, Tamura K, Hashimoto K. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring. J Cardiovasc Pharmacol 2000;36:510–515.

    Article  PubMed  CAS  Google Scholar 

  318. Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K. Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol 2000;169:8–16.

    Article  PubMed  CAS  Google Scholar 

  319. Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH. The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. Clin Ther 1999;21:1171–1181.

    Article  PubMed  CAS  Google Scholar 

  320. Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH. The effect of terfenadine on the cardiac pharmacodynamics of sparfloxacin. Clin Ther 1999;21:1514–1524.

    Article  PubMed  CAS  Google Scholar 

  321. Iannini PB, Doddamani S, Byazrova E, Curciumara I, Kramer H. Risk of torsades de pointes with non-cardiac drugs. prolongation of QT interval is probably a class effect of fluoroquinolones [letter]. BMJ 2001;322:46–47.

    Article  PubMed  CAS  Google Scholar 

  322. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68:658–666.

    Article  PubMed  CAS  Google Scholar 

  323. Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004;44:464–473.

    Article  PubMed  CAS  Google Scholar 

  324. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73:292–303.

    Article  PubMed  CAS  Google Scholar 

  325. Doig JC. Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Safety 1997;17:265–275.

    Article  PubMed  CAS  Google Scholar 

  326. Roden DM. A practical approach to torsades de pointes. Clin Cardiol 1997;20:285–290.

    Article  PubMed  CAS  Google Scholar 

  327. Janeira LF. Torsades de pointes and long QT syndromes. Clin Fam Phys 1995;52:1447–1453.

    CAS  Google Scholar 

  328. Yu C-C, Kelly PA, Burckart GJ, Zeevi A. Sirolimus inhibition of lymphocyte proliferation is not antagonized by ciprofloxacin and other quinolone antibiotics. Transplant Proc 2001;33:2989–2991.

    Article  PubMed  CAS  Google Scholar 

  329. Kelly PA, Burckart GJ, Anderson D, Shapiro R, Zeevi A. Ciprofloxacin does not block the antiproliferative effect of tacrolimus [letter]. Transplantation 1997;63:172–173.

    Article  PubMed  CAS  Google Scholar 

  330. Roberge RJ, Kaplan R, Frank R, Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000;36:160–163.

    Article  PubMed  CAS  Google Scholar 

  331. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004;42:295–297.

    Article  PubMed  Google Scholar 

  332. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002;113:232–234.

    Article  PubMed  Google Scholar 

  333. LeBlanc M, Belanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy 2004;24:926–931.

    Article  PubMed  Google Scholar 

  334. Khovidhunkit W, Sunthornyothin S. Hypoglycemia, hyperglycemia, and gatifloxacin. Ann Intern Med 2004;141:969.

    PubMed  Google Scholar 

  335. Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC. Gatifloxacin-induced hyperglycemia. Ann Intern Med. 2004;141:968–969.

    PubMed  Google Scholar 

  336. Gatifloxacin(Tequin®) [package insert]. Princeton, NJ: Bristol Myers-Squibb, October 2002.

    Google Scholar 

  337. Frothingham R. Gatifloxacin associated with a 56-fold higher rate of glucose homeostasis abnormalities than comparator quinolones in the FDA spontaneous reporting database. Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October–November 2004; Abstract A-1092.

    Google Scholar 

  338. Grasela D, Lacreta F, Kollia G, Randall D, Stoltz R, Berger S. Lack of effect of multipledose gatifloxacin (GAT) on oral glucose tolerance (OGTT), glucose and insulin homeostasis, and glyburide pharmacokinetics (PK) in patients with type II non-insulin-dependent diabetes mellitus (NIDDM). Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1999. Abstract 196.

    Google Scholar 

  339. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000;20(6 pt 2):49S–58S.

    Article  PubMed  CAS  Google Scholar 

  340. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000;20(6 pt. 2):76S–86S.

    Article  PubMed  CAS  Google Scholar 

  341. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2003.

    Google Scholar 

  342. Szentmary N, Kraszni M, Nagy ZZ. Interaction of indomethacin and ciprofloxacin in the cornea following phototherapeutic keratectomy. Graefes Arch Clin Exp Ophthalmol 2004;242:614–616.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for the Study of Geriatric Pharmacotherapy, College of Pharmacy, University of Minnesota-Minneapolis, Minneapolis, MN

    David R. P. Guay Pharmd (Professor, Clinical Specialist)

  2. Partnering Care Senior Services, Division of Geriatrics, HealthPartners, Minneapolis, MN

    David R. P. Guay Pharmd (Professor, Clinical Specialist)

Authors
  1. David R. P. Guay Pharmd
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Discovery Medicine-Antivirals, GlaxoSmithKline, Research Triangle Park, NC

    Stephen C. Piscitelli PharmD (Director) (Director)

  2. College of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, IL

    Keith A. Rodvold PharmD (Professor of Pharmacy Practice and Associate Professor of Medicine in Pharmacy) (Professor of Pharmacy Practice and Associate Professor of Medicine in Pharmacy)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Guay, D.R.P. (2005). Quinolones. In: Piscitelli, S.C., Rodvold, K.A. (eds) Drug Interactions in Infectious Diseases. Infectious Disease. Humana Press. https://doi.org/10.1385/1-59259-924-9:215

Download citation

  • DOI: https://doi.org/10.1385/1-59259-924-9:215

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-455-5

  • Online ISBN: 978-1-59259-924-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation